Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Ticker
- $HALO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- San Diego, United States
- Website
- halozyme.com
HALO Metrics
BasicAdvanced
$12bn
30.10
$3.38
-
-
Price and volume
Market cap
$12bn
52-week high
$104.78
52-week low
$61.23
Average daily volume
2.2m
Financial strength
Current ratio
2.709
Quick ratio
1.994
Long term debt to equity
1,372.107
Total debt to equity
1,517.687
Interest coverage (TTM)
46.52%
Profitability
EBITDA (TTM)
1,050.688
Gross margin (TTM)
76.27%
Net profit margin (TTM)
24.86%
Operating margin (TTM)
56.77%
Effective tax rate (TTM)
29.10%
Revenue per employee (TTM)
$3,930,000
Management effectiveness
Return on assets (TTM)
25.49%
Return on equity (TTM)
173.67%
Valuation
Price to earnings (TTM)
30.096
Price to revenue (TTM)
7.192
Price to book
80.87
Price to tangible book (TTM)
-8.53
Price to free cash flow (TTM)
23.08
Free cash flow yield (TTM)
4.33%
Free cash flow per share (TTM)
4.41
Growth
Revenue change (TTM)
41.15%
Earnings per share change (TTM)
-22.52%
3-year revenue growth (CAGR)
29.08%
10-year revenue growth (CAGR)
27.30%
3-year earnings per share growth (CAGR)
25.71%
10-year earnings per share growth (CAGR)
20.52%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.